arrow
L

Louise R. Rodino-Klapac

sarepta therapeutics inc.
H指数:45
被引数:9,911

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Two-Year Outcomes Following Delandistrogene Moxeparvovec Treatment in Ambulatory Patients with Duchenne Muscular Dystrophy: Phase 3 EMBARK Trial

杜氏肌营养不良症非卧床患者接受Delandistrogene Moxeparvovec治疗后的两年结果:EMBARK三期临床试验

2026-01-100
OAAI
Pharmacokinetic and Pharmacodynamic Evaluation of Bidridistrogene Xeboparvovec in an Aged Murine Model of Limb-Girdle Muscular Dystrophy Type 2E/R4

Bidridistrogene Xeboparvovec 在 2E/R4 型 limb-girdle 肌营养不良老年小鼠模型中的药代动力学和药效动力学评估

2025-10-300
PRE
Quantitative Muscle Magnetic Resonance Outcomes in Patients With Duchenne Muscular Dystrophy An Exploratory Analysis From the EMBARK Randomized Clinical Trial

杜氏肌营养不良症患者定量肌肉磁共振结局:EMBARK随机临床试验的探索性分析

2025-05-120
PRE
Immunologic investigations into transgene directed immune-mediated myositis following delandistrogene moxeparvovec gene therapy

delandistrogene moxeparvovec基因治疗后转基因定向免疫介导的肌炎的免疫学研究

2025-01-021
OAAI
AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial

AAV基因治疗杜氏肌营养不良症: EMBARK 3期随机试验

2024-10-093
OAAI
Integrated Analyses of Data from Clinical Trials of Delandistrogene Moxeparvovec (SRP-9001) in Duchenne Muscular Dystrophy (DMD)

Duchenne肌营养不良症 (DMD) 的dlandistrogene Moxeparvovec (SRP-9001) 临床试验数据的综合分析

2023-04-250
PRE
A phase 2 clinical trial evaluating the safety and efficacy of delandistrogene moxeparvovec for treating patients with Duchenne muscular dystrophy
2022-03-010
OA
Current Clinical Applications of In Vivo Gene Therapy with AAVs

AAVs体内基因治疗的临床应用现状

2021-02-01452
OAAI